Fig. 7: Clinical relevance of the SF3B1 mutation. | Nature Communications

Fig. 7: Clinical relevance of the SF3B1 mutation.

From: Somatic SF3B1 hotspot mutation in prolactinomas

Fig. 7

a The gender distribution is shown within different groups (mutant group n = 45 and wild group n = 182). b The PRL level (PRL/tumor size) in SF3B1 mutant and SF3B1 wild-type prolactinomas are displayed (mutant group n = 40 and wild group n = 159). Results are given as mean ± SD. c Kaplan–Meier survival plots of 199 prolactinomas patients stratified by SF3B1 mutation status (mutant group n = 40 and wild group n = 159). d Schematic representation showing the proposed mechanisms of how SF3B1 mutations lead to increased PRL secretion and tumor growth in prolactinomas. The p values by chi-square test in a and by two-tailed Mann–Whitney test in b are indicated. The p value by log-rank (Mantel–Cox) test is indicated in c. Source data are provided as a Source Data file.

Back to article page